Tag: adamas pharmaceuticals
January 2, 2020
Adamas Announces Settlement of Patent Litigation with Sandoz
Adamas has entered into a settlement agreement with Sandoz resolving its ongoing litigation concerning Sandoz’s new drug application. September 20, 2019
Adamas Announces Data for GOCOVRI in Parkinson’s Disease
Adamas Pharmaceuticals (NASDAQ:ADMS) has announced presentation of new data on GOCOVRI to treat dyskinesia in patients with Parkinson’s disease. As...
September 12, 2019
5 Alzheimer’s Disease Treatment Stocks on the NASDAQ
A report from Reports and Data suggests the overall Alzheimer's market will be worth US$12.43 billion by 2026. December 19, 2018
Adamas Announces Issuance of New U.S. Patent Covering GOCOVRI
Adamas Pharmaceuticals (Nasdaq:ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today announced that a new... October 4, 2018